How Good is Radiofrequency RFA for Relief of Symptoms and Decreasing Nodules Size?
My comments on the 2012 article with updates to 2017. RFA is still not avaiable in the USA but you still can avoid surgery by going to Korea or Italy with my evaluation and referral.You will have a short stay just for the treatment as they accept my evaluation and don’t repeat it.
Call Matt 310-393-8860 or firstname.lastname@example.org for details.
Richard Guttler MD,FACE,ECNU
Dong Gyu Na, et al
- Efficacy of RF ablation for benign thyroid nodules can be evaluated by symptom score, cosmetic score, % volume reduction ([initial volume – final volume] × 100/initial volume).
- Therapeutic success rate (volume reduction > 50%).
- Color-Doppler US is helpful for the evaluation of presence of vascularity within the ablated nodule, which suggests a possible undertreated area of a nodule.
- For AFTN evaluation with a thyroid scan, serum thyroid hormone, and thyrotrophin concentration.
- The efficacy of RF ablation for recurrent thyroid cancers can be evaluated by % volume reduction and serum thyroglobulin concentrations.
- Radiofrequency ablation cannot remove thyroid nodules immediately; rather, it induces the necrosis and involution of thyroid nodules, resulting in volume reduction and improvements in clinical symptoms, with the efficacy of RF ablation similar to that of thyroid surgery.
- Hyperthyroidism caused by AFTN can be cured or improved by RF ablation.
- Although most patients have shown improvements after a single session of RF ablation, others may require several sessions to achieve complete ablation.
- The reduction in nodule volume after RF ablation has been found to range from 33-58% at one month and from 51% to 92% at six months.
- RF ablation can be used for locoregional control of cancer or improvement of cancer related symptoms in patients with recurrent thyroid cancer who have a high surgical risk and refuse repeated surgery.
- RF ablation of recurrent thyroid cancers in the neck resulted in a mean volume reduction of 56% to 93%, with 42% to 58% of nodules completely disappearing, 64% of patients experiencing symptom improvement, and serum thyroglobulin concentration decreasing.